Vaxcyte Shares Rise on Positive Phase 3 Data for Pneumonia Vaccine Candidate
Vaxcyte’s stock surged approximately 32% in early Monday trading following the release of positive topline results from its phase 3 trial, OPUS-1. The study evaluated VAX-31, a pneumococcal conjugate vaccine candidate designed as an alternative to Merck's existing product. The data showed that VAX-31 met non-inferiority and immunogenicity benchmarks compared to the competitor’s offering. The trial results represent a significant milestone for Vaxcyte in its efforts to bring a broader-spectrum pneumococcal vaccine to market, potentially capturing share from Merck's current product. The positive data has sparked optimism among investors about the company's pipeline and future commercial prospects.
Topics: biotech immunogenicity non-inferiority trial vaccine